Ju Bo Liu
Direktor/Vorstandsmitglied bei BIOTON S.A.
Aktive Positionen von Ju Bo Liu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BIOTON S.A. | Direktor/Vorstandsmitglied | 01.01.2022 | - |
NovoTek Pharmaceuticals Ltd.
NovoTek Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Yifan Pharmaceutical Co., Ltd., NovoTek Pharmaceuticals Ltd. is a Chinese pharmaceutical company that manufactures pharmaceutical products. The company is based in Hong Kong, Hong Kong. The company was founded by Ju Bo Liu. Ju Bo Liu has been the CEO since incorporation. NovoTek Pharmaceuticals was acquired by Yifan International Pharmaceutical Co., Ltd. from Merrylake International Ltd. on January 25, 2018 for $20.60 million. | Vorstandsvorsitzender | - | - |
Gründer | - | - | |
Novotek Medicinal Technology Development Co. Ltd. | Vorstandsvorsitzender | 01.08.2009 | - |
Beijing Novotek Medicinal Technology Development Co. Ltd. | Vorstandsvorsitzender | 01.09.2009 | - |
Gründer | 01.09.2009 | - | |
Itabmed Co., Ltd.
Itabmed Co., Ltd. BiotechnologyHealth Technology ITabMed Co., Ltd. is a Chinese clinical-stage biotech company that focuses on the discovery and development of immunotherapy products to treat cancer. The company is based in Shanghai, China. ITabMed Co. was founded in 2020 by Xiaoqiang Yan, who has been the CEO since 2020. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Ju Bo Liu
Ehemalige bekannte Positionen von Ju Bo Liu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SCIGEN LIMITED | Direktor/Vorstandsmitglied | 10.02.2017 | 07.08.2018 |
NovoTek Therapeutics, Inc. | Vorstandsvorsitzender | 01.08.2009 | 01.03.2018 |
Huayuanlong Medicinal Technology Development Co. Ltd. | General Counsel | 01.08.1997 | 01.02.2001 |
Vertrieb & Marketing | 01.08.1997 | 01.02.2001 |
Ausbildung von Ju Bo Liu
University of Toronto | Doctorate Degree |
Shenyang Pharmaceutical University | Undergraduate Degree |
Statistik
International
China | 7 |
Singapur | 2 |
Kanada | 2 |
Operativ
Chief Executive Officer | 4 |
Director/Board Member | 3 |
Founder | 3 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BIOTON S.A. | Health Technology |
Private Unternehmen | 7 |
---|---|
SciGen Pte Ltd.
SciGen Pte Ltd. Pharmaceuticals: MajorHealth Technology SciGen Pte Ltd. engages in the development, manufacturing, and marketing of biopharmaceutical products. It operates through following segments: Singapore, Australia, Korea, Thailand, Philippines, China, and Others. The Singapore segment comprises of corporate office functions, sales, and marketing. The Australia, Korea, Thailand, and Philippines segments deal with sales and marketing activities. The China segment is involved in regulatory activities. The Others segment covers operations on in Indonesia, Pakistan, Vietnam, Hong Kong, Myanmar, Malaysia, and profit sharing income on sale of insulin. The firm's products include SciLin, SciTropin A, SciLocyte, SciTrace 5 Injection, and Heri Injection. The company was founded by Saul Akerib Mashaal in 1988 and is headquartered in Singapore. | Health Technology |
NovoTek Therapeutics, Inc. | |
NovoTek Pharmaceuticals Ltd.
NovoTek Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Yifan Pharmaceutical Co., Ltd., NovoTek Pharmaceuticals Ltd. is a Chinese pharmaceutical company that manufactures pharmaceutical products. The company is based in Hong Kong, Hong Kong. The company was founded by Ju Bo Liu. Ju Bo Liu has been the CEO since incorporation. NovoTek Pharmaceuticals was acquired by Yifan International Pharmaceutical Co., Ltd. from Merrylake International Ltd. on January 25, 2018 for $20.60 million. | Health Technology |
Novotek Medicinal Technology Development Co. Ltd. | |
Huayuanlong Medicinal Technology Development Co. Ltd. | |
Beijing Novotek Medicinal Technology Development Co. Ltd. | |
Itabmed Co., Ltd.
Itabmed Co., Ltd. BiotechnologyHealth Technology ITabMed Co., Ltd. is a Chinese clinical-stage biotech company that focuses on the discovery and development of immunotherapy products to treat cancer. The company is based in Shanghai, China. ITabMed Co. was founded in 2020 by Xiaoqiang Yan, who has been the CEO since 2020. | Health Technology |